Real-World Study: Treatment Persistence in Pulmonary Arterial Hypertension Patients
The study analysed real-world data to compare treatment persistence and adherence among PAH patients on ERAs in Japan. Results showed significantly higher persistence with a medication compared to the other two medications.
Case Study: Rare disease (PAH) – Patient finding
The Prospection Platform helped a top pharmaceutical company simplify complex brand decision making surrounding Pulmonary Arterial Hypertension (PAH) to support patient programs with the aim to deliver earlier diagnoses and better referral programs. Our analysis identified anomalies across geographies for diagnosis and referrals by specialties. We equipped our client with these on-demand insights that enabled them to determine PAH stakeholders and decide how to achieve earlier diagnosis, better referrals, and improved patient outcomes.
Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience
This paper aimed to study treatment persistence and mortality using a single-pill, fixed-dose combination tablet compared with a two-pill combination for hypertension.y using a single-pill, fixed-dose combination
tablet compared with a two-pill combination for hypertension.
Are high coronary risk patients missing out on lipid-lowering drugs in Australia?
This study examined whether high coronary risk patients in Australia, where use of lipid-lowering drugs (LLD) is very high by international standards, are receiving LLD.
